Opevesostat is an orally bioavailable, non-steroidal, selective inhibitor of the mitochondrial enzyme CYP11A1, which converts cholesterol to pregnenolone, the first step in steroid hormone synthesis. By blocking this step it suppresses production of all steroid hormones and their precursors. It is being studied in metastatic prostate cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.